Compare RH & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RH | SRPT |
|---|---|---|
| Founded | 1979 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 2011 | 2000 |
| Metric | RH | SRPT |
|---|---|---|
| Price | $166.81 | $20.69 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 14 | 29 |
| Target Price | ★ $167.00 | $25.85 |
| AVG Volume (30 Days) | 866.4K | ★ 3.6M |
| Earning Date | 06-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.31 | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | $1,193,046,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $8.39 | N/A |
| Revenue Next Year | $9.44 | N/A |
| P/E Ratio | ★ N/A | $7.02 |
| Revenue Growth | ★ 24.52 | 15.58 |
| 52 Week Low | $106.30 | $10.42 |
| 52 Week High | $256.78 | $25.32 |
| Indicator | RH | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 60.98 | 69.95 |
| Support Level | $138.61 | $20.61 |
| Resistance Level | $202.40 | $23.54 |
| Average True Range (ATR) | 9.23 | 0.99 |
| MACD | 0.48 | 0.49 |
| Stochastic Oscillator | 82.96 | 95.38 |
RH is a luxury furniture and lifestyle retailer primarily operating in the $136 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories, including furniture, lighting, textiles, bath, decor, and is growing the presence of its hospitality business with 25 restaurant locations, including RH Guesthouse. RH innovates, curates, and integrates products, categories, services, and businesses across channels and brand extensions (RH Modern and Waterworks, for example). RH is fully integrated across channels and is positioned to broaden its addressable market over the next decade via expanding abroad, its World of RH digital platform (highlighting offerings outside of home furnishings), and offerings in architecture, media, and more.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.